Joseph Thome
Stock Analyst at TD Cowen
(0.70)
# 4,035
Out of 5,042 analysts
17
Total ratings
40%
Success rate
-11.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Initiates: Buy | $95 | $70.02 | +35.68% | 1 | Sep 24, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Buy | n/a | $61.18 | - | 1 | May 13, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $22.16 | - | 1 | Nov 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $418.58 | -4.44% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $25.93 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $29.80 | +14.09% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $5.33 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $2.89 | - | 1 | Mar 5, 2024 | |
| PTCT PTC Therapeutics | Maintains: Market Perform | $32 → $30 | $66.40 | -54.82% | 2 | Mar 1, 2024 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | n/a | $40.76 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.07 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $129.55 | +0.35% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $25.60 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.83 | - | 1 | Nov 23, 2021 |
Mirum Pharmaceuticals
Sep 24, 2025
Initiates: Buy
Price Target: $95
Current: $70.02
Upside: +35.68%
Bright Minds Biosciences
May 13, 2025
Initiates: Buy
Price Target: n/a
Current: $61.18
Upside: -
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $22.16
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $418.58
Upside: -4.44%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $25.93
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $29.80
Upside: +14.09%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $5.33
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $2.89
Upside: -
PTC Therapeutics
Mar 1, 2024
Maintains: Market Perform
Price Target: $32 → $30
Current: $66.40
Upside: -54.82%
Xenon Pharmaceuticals
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $40.76
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.07
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $129.55
Upside: +0.35%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $25.60
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.83
Upside: -